Business
Results of General Meeting
Results of General Meeting.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 1099S\n Oxford BioDynamics PLC\n 11 November 2021\n \n \n \n \n 11 November 2021\n \n \n \n \n \n Oxford Biodynamics Plc\n \n \n \n \n \n Results of General Meeting\n \n \n \n \n \n Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing targeted clinical diagnostic tests for immune health using its EpiSwitch® 3D genomics technology, announces that both resolutions proposed \n at the Company's General Meeting, held earlier today, were duly passed. Holders of 63,233,927 shares (representing 63% of the issued share capital of the Company) submitted proxy votes. Over 99% of the votes cast were in favour of each of the resolutions. Accordingly, warrants to subscribe for 7,791,803 new ordinary shares at an exercise price of 58.125 pence per new Ordinary Share have been issued to Armistice Capital Master Fund Limited.\n \n -ENDS-\n \n \n \n \n \n For further details please contact: \n \n \n \n \n \n \n \n \n \n Oxford BioDynamics Plc\n \n \n \n \n Tel: +44 (0)1865 518910\n \n \n \n \n \n \n Jon Burrows, CEO\n \n \n Paul Stockdale, CFO\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Shore Capital - Nominated Adviser and Broker\n \n \n \n \n Tel: +44 (0)20 7408 4090\n \n \n \n \n \n \n Advisory: Stephane Auton / John More\n \n \n Broking: Fiona Conroy\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Instinctif Partners\n \n \n \n \n Tel: +44 (0)20 7457 2020\n \n \n \n \n \n \n Melanie Toyne-Sewell / Nathan Billis\n \n \n \n \n [email protected]\n \n \n \n \n \n \n \n \n \n NOTES TO EDITORS:\n \n \n About Oxford BioDynamics Plc\n \n \n Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. \n \n \n In March 2021, the Company launched its first commercial prognostic test, \n \n EpiSwitch\n \n \n ®\n \n \n \n \n \n CST\n \n (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, \n \n EpiSwitch® Explorer Array Kit\n \n . Its next product will be EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profi...